Odylia Therapeutics will be discussing our RPGRIP1 Gene Therapy program to treat vision loss in patients diagnosed with Leber Congenital Amaurosis 6 (LCA6). Join us to learn more about Odylia Therapeutics and the progress of our gene therapy program, as well as next steps.

Follow the link to sign-up and receive a zoom link: https://odyliatherapeutics.salsalabs.org/rpgrip1zoom0/index.html

Share this information with anyone who might be interested or your social media networks.